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This review refers to the origin and current state of the assessment of the SpondyloArthritis International Society
(ASAS) criteria for the classification of axial and peripheral spondyloarthritis (SpA) and the possible implications in
the pediatric population. The ASAS criteria evolved from the idea that the earlier the recognition of patients with
ankylosing spondylitis, the better the efficacy of tumor necrosis factor blockers. Strategies included the
development of new concepts, definitions, and techniques for the study of clinical signs and symptoms. Of
relevance, the new definition of inflammatory back pain (IBP) and the introduction of sacroiliitis by magnetic
resonance imaging represented the most important advance in the early identification of AS in the
“pre-radiographic stage” of the disease. AS is considered in this paper as a disease continuum with symptoms
depending on age at onset. The application of those specific strategies in children and adolescents with SpA seems
limited because the most important manifestation in the early stage of disease is not IBP, but peripheral arthritis
and enthesitis. In this instance, the logical approach to juvenile onset SpA according to ASAS criteria should not be
through the axial criteria but rather the peripheral set of criteria.
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Ankylosing spondylitis (AS) is the prototype of a group of
arthritis conditions collectively called SpA1, which
includes undifferentiated SpA (u-SpA), reactive arthritis
(ReA), and subsets of psoriatic arthritis (PsA), Crohn’s
disease, and ulcerative colitis. The characteristics of these
conditions include axial and peripheral enthesitis and
arthritis, certain extrarticular manifestations, family aggre-
gation, and HLA-B27 association. The spectrum of SpA
spans from early, undifferentiated forms to well-defined
diseases such as AS. Despite the fact that u-SpA might be
the initial stage of any definite form of SpA, mainly AS, aCorrespondence: burgosv@prodigy.net.mx
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reproduction in any medium, provided the ornumber of patients may have only a short and mild course
of symptoms followed by complete remission of inflam-
mation and no permanent consequences.
In contrast to this mild, self-limited disease, AS is the
result of a long-standing process that combines chronic in-
flammation and new bone formation, mainly at the tendon
and ligament attachments to bones. AS is usually character-
ized by inflammatory back pain (IBP) and morning stiffness,
progressive reduction of the spinal mobility, lower-limb
joint and entheses involvement, anterior uveitis, and non-
specific inflammatory bowel disease (IBD) [1]. The preva-
lence of AS in the population is linked to that of HLA-B27
and occurs most frequently in HLA-B27 young males [2].
The diagnosis of AS is usually made eight to ten years
after the onset of complaints (mostly IBP) and depends
on the presence of axial signs and symptoms andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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The course of the disease varies from one individual to
another. Disease activity may show a fluctuating pattern
and the structural damage, particularly late spinal changes
such as syndesmophyte formation and the notorious
“bamboo spine”, that illustrates the relatively slow progres-
sion. With such variation in disease course, the long-term
consequences of AS, particularly health related quality of
life (HRQoL) and functioning, can differ among the indivi-
duals that suffer from the disease [4-6]. Finally, some data
suggest that the mortality of AS is increased when com-
pared to that of the general population [7,8].
The term “ankylosing spondylitis” means “stiff verte-
brae” (from the Greek ankylos and spondylos). Alternative
names, most in disuse, include seronegative polyarthritis,
seronegative spondarthritis, seronegative spondyloarthri-
tis, seronegative spondylarthropathies, spondyloarthritides.
The stereotypic AS patient has a long-standing and severe
disease characterized by spinal deformity and vertebral
ankylosis for which no effective therapy has been available.
Yet, it is clear that not all patients with AS fit into that
stereotype. Moreover, the introduction of tumor necrosis
factor (TNF) blockers has resulted in the control of signs
and symptoms related to inflammation and the improve-
ment of most outcome measures, including HRQoL, par-
ticularly in patients with a short disease duration.
Within the last ten years, clinicians have tried to
recognize and diagnose AS in the early inflammatory stageTable 1 Modified New York criteria for ankylosing spondylitis
A. Diagnosis*
1. Clinical criteria
a) Low back pain and stiffness for more tan three months, which improve
b) Limitation of motion of the lumbar spine in both the sagittal and front
c) Limitation of chest expansion relative to normal values correlated for a
2. Radiological criterion:
Sacroiliitis grade ≥2 bilaterally or grade 3–4 unilaterally
B. Grading
1. Definite ankylosing spondylitis is considered if the radiologic criteria is ass
2. Probable ankylosing spondylitis if:
a) Three clinical criteria are present
b) The radiologic criterion is present without any signs or symptoms satis
Radiographic criteria
Grade 0 = normal
Grade 1 = suspicious changes
Grade 2 =minimal abnormality – small localized areas with erosions or sclero
Grade 4 = severe abnormality –total ankylosis.
*The modified New York criteria for ankylosing spondylitis are mostly used for class
All three clinical and the radiographic criteria refer exclusively to axial involvement,
The proportion of children and adolescents that fulfill those criteria before they rea
combination of peripheral and axial symptoms.
It is assumed that stated otherwise, publications on ankylosing spondylitis never reof the process that ultimately leads to bone proliferation
[9,10]. The purpose of this effort was to treat AS in the
early pre-radiographic stage of the disease with TNF-block-
ers and prevent its long-term consequences. These strat-
egies were utilized to identify the early inflammatory stage
of the disease in patients by focusing on the definition, clas-
sification, and diagnostic criteria of IBP and SpA, including
the use of magnetic resonance imaging (MRI) for the de-
tection of sacroiliac and vertebral inflammation, as well as
the use of HLA-B27 testing. Ultimately, the Assessment of
SpondyloArthritis International Society (ASAS) developed
concept and classification criteria for axial SpA [11] and
then for peripheral SpA [12]. At the same time, we learned
about the efficacy of TNF blockers in controlling inflam-
mation, but probably not in suppressing bone proliferation.
In this paper, the characteristics and development of
the ASAS criteria for the classification of axial and per-
ipheral SpA are reviewed. These classification criteria
and their possible role in the classification of children
and adolescents with SpA are examined by defining and
comparing the juvenile and adult criteria as they apply
to pre-radiographic AS, AS, u-SpA, and ASAS axial and
peripheral SpA.
The relationship between adult and juvenile-onset AS and
SpA
Although the most common age at onset of AS is
around 25 years, a variable percentage of patients startref. [3]
s by exercise, but is not relieved by rest
al planes
ge and sex
ociated with at least one clinical criterion
fying the clinical criteria (other causes of sacroiliitis should be considered)
sis, without alteration in the joint width
ification.
including the spinal, costovertebral, costosternal, and sacroiliac joints.
ch the age 17 years is probably <15%. In such a case they usually have a
fer to definite or probable disease, but to definite ankylosing spondylitis.
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fact that juvenile and adult onset forms differ in their
mode of presentation, both forms represent a disease
continuum in which age-related factors might play a
role in clinical expression. Compared with juvenile
onset AS, patients with adult onset disease have a
higher prevalence of axial symptoms and, in contrast, a
much lower prevalence of peripheral enthesitis and
arthritis in the initial years of the disease [13-22]. Incon-
sistent genetic and minor synovial histologic differences
between adults and juvenile patients have been also
described [23-26].
The consequences of AS seem more severe in juvenile
patients [13,15-17,19-22]. Despite the fact that there are
no studies comparing other SpA in adult and childhood
subjects, the information available up to now on SpA-
related, u-SpA, and ReA does not reveal major differences
between the two age-at-onset populations. No important
differences in pathogenesis or therapeutics have been
reported. Thus, the concept that juvenile and adult onsetu-SpA or axial SpA 
Pre-radiographic stage 
Inflammatory back pain 
Peripheral arthritis 
and enthesitis 
Active sacroiliitis by MRI 
Peripheral arthritis and 
enthesitis 
Inflammatory back pain  


































   
 
Less than 5 years 5 to
Figure 1 The modified schematic representation of Rudwaleit’s schem
spondyloarthritis (u-SpA) to ankylosing spondylitis (AS) in the contex
idea that axial SpA is mostly representative of adult-onset patients (upper p
and adolescents with juvenile-onset SpA is that of peripheral SpA (lower p
reports. Note that during the interval between disease onset and the 5th y
signs in juvenile-onset SpA are peripheral arthritis and enthesitis and not in
peripheral symptoms, (small fonts) is the most important characteristic in a
patients with both juvenile and adult onset SpA fulfilling the modified New
after onset. Imaging of the sacroiliac joints, particularly the early inflammat
study of adult patients with IBP. This approach does not seem the logical i
the initial years of disease. While the demonstration of edema in the sacro
earliest the treatment, the better the response, the indications for early trea
factor (TNF) blockers could mostly rely on peripheral symptoms. Regarding
probable that in juvenile-onset patient this stage takes a long time to deveAS represent the same disease has important implications
in the clinical and therapeutic field. Indeed, this concept
does not consider the subgroup of PsA in younger chil-
dren (mostly girls, with dactylitis, polyarthritis, and anti-
nuclear antibodies).
In keeping with the traditional idea of Moll and
Wright about the SpA group [27], we conceptualize
juvenile-onset SpA, including AS, as a group of HLA-
B27–associated pediatric rheumatic diseases character-
ized by enthesitis and arthritis involving in most cases
the lower extremities in the initial years and, in a vari-
able proportion of cases, the sacroiliac and spinal joints
some years later [28]. This concept differs from that of
the enthesitis related arthritis (ERA) and PsA subgroups
of juvenile idiopathic arthritis (JIA) classification of the
International League for Associations of Rheumatology
(ILAR) [29]. In that classification, the overlapping of
diagnostic manifestations between two or more sub-
groups excludes definite diagnosis and puts any such
case in the “undifferentiated arthritis” category.Ankylosing spondylitis 
Radiographic stage 
al arthritis and 
thesitis 
tory back pain 
itis by X-rays 
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 10 years More than 10 years 
e [49] on the transition of undifferentiated juvenile-onset
t of axial and peripheral SpA. Note: In this model, we present the
anel) whereas the subset that could mostly be adapted to children
anel). Time to transition is an estimation based on scarce published
ear of symptoms, the most frequent and characteristic symptoms and
flammatory back pain (small fonts; IBP). In contrast, IBP, and not
dult patients. Beyond the 5th year of disease, the proportion of
York criteria for AS [3] increases to reach a maximum around 10 years
ory stage by magnetic resonance imaging (MRI) is essential in the
n the study of juvenile-onset SpA since IBP occurs in less than 15% in
iliac joints by MRI has therapeutic implications in adult-onset SpA –the
tment of children and adolescents with SpA with tumor necrosis
the ostechondral proliferative stage of spinal involvement, it is only
lop, perhaps similar to that seen in adults.
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The rationale for the development of the ASAS axial and
peripheral classification criteria was to facilitate the recog-
nition and detection of patients with back pain at risk of
AS. It is widely known that most patients with early AS
present with undifferentiated manifestations, most charac-
teristically with IBP, less frequently with peripheral arthritis
and enthesitis, and rarely with extrarticular manifestations.
Thus, the initial stage of AS corresponds to that of u-SpA,
a group that accounts for an important proportion of SpA
in the community [30,31], specialized clinics [32], and
multiplex-case families [33,34]. The initial descriptions of
u-SpA dated back to 1983 and 1984 [35,36] and consisted
of patients fulfilling the Amor, et al. [37] as well as the
European Spondylarthropathy Study Group (ESSG) [38]
classification criteria for SpA, but not fulfilling criteria for
AS or the specific diagnostic features of ReA, PsA, Crohn’s
disease, and ulcerative colitis. Besides IBP, peripheral arth-
ritis and enthesitis have been prominent features at onset
in patients with u-SpA [39,40]. In retrospect, most patients
with u-SpA fulfill AS criteria within five to ten years after
onset (Figure 1) [41-49].
Peripheral u-SpA has a childhood counterpart, which is
traceable to clinical descriptions embraced under terms
such as “probable Still’s disease” [50], type II (HLA-B27 +





























Figure 2 Percentage of adult and juvenile onset patients with undiffe
throughout the course of the disease as reported in retrospective stu
population included in the study, entry criteria, and the type of assessment
patients include a moderately high proportion of patients with peripheral a
consider AS the outcome measure, but some others referred to other para[51], atypical SpA [52], and most clearly to HLA-B27-
associated SpA and enthesopathy in children [53] as well
as the seronegative enthesopathy and arthropathy (SEA)
syndrome [54]. This progression of juvenile-onset u-SpA
to AS starts in most cases with peripheral symptoms and
follows a clinical course leading to AS within ten years of
disease [55-61] (Figure 1).
There are important variations in the proportion of
adult-onset and juvenile-onset patients with u-SpA fulfill-
ing AS criteria that occur throughout the disease courses
in various studies (Figure 2). The reasons for these varia-
tions are probably related to the characteristics of the
population included in the study, patient entry and inclu-
sion criteria, design of the study, as well as the type and
periodicity of clinical assessments. Information on those
who remain in the undifferentiated stage or on those evolv-
ing into other SpA (i.e.: PsA) as well as on those entering
into sustained remission, is limited in these studies.
In adults with u-SpA, progression to AS has been incon-
sistently associated with several factors. These include uve-
itis [41,46,48], HLA-B27 [41,43], alternate gluteal pain [43],
peripheral arthritis [44], a high erythrocyte sedimentation
rate [41], an elevated C- reactive protein (CRP) [46], recur-
rent oligoarthritis [45], and a low-grade radiographic sacroi-
liitis [46]. AS risk factors include low-grade radiographic
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rentiated SpA (u-SpA) progressing to ankylosing spondylitis (AS)
dies. Note: Variations are probably related to the characteristics of the
s carried out. Interestingly, most references related to adult-onset
rthritis in combination or not with axial symptoms. Most studies
meters, for example radiographic sacroiliitis.
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sacroiliitis and AS associate in univariate or multivariate
analyses with a somewhat different set of factors at dif-
ferent intervals such as HLA-B27 [54,61], DRB1*04
[61,63], age at onset of symptoms, male sex, and family
history of AS [61], arthritis [54], polyarthritis [64],
enthesitis [60,61], tarsitis [60], hip involvement [61,63],
axial involvement [60-64], and psoriasis [61] (Table 2).
Prospective data of patients with axial SpA according
to ASAS criteria or IBP differ in some important aspects
from retrospective studies. These differences are seen in
the prospective German Spondyloarthritis Inception Co-
hort (GESPIC) [65], the Maastricht’s early SpA clinic
population (ESPAC) [66], as well as the Leeds [67], and
French (Devenir des Spondylarthropathies Indifféren-
ciées Récentes or DESIR) [68] IBP clinics.
GESPIC [65] consisted of 462 patients with axial SpA,
including 236 with AS of whom 50.4% had already devel-
oped AS within five years of symptoms. In these patients,
male sex was predictive of radiographic sacroiliitis and >1
syndesmophyte and CRP ≤6 mg/L for >1 syndesmophyte
and >1 bridging syndesmophyte. In ESPAC [66], 14
patients (21%) out of 68 with IBP had already developed
AS within <2 years of symptoms, 24% had PsA and 15%
each had IBD and uveitis. In the Leeds clinic data [67], 13
patients out of 40 (33%) with IBP had AS within two yearsTable 2 Variables associated with the likelihood of developin




Onset age ≥8 years 21.12 2.809-159.48
Family history of AS 9.94 3.67-26.92
HLA-B27 10.35 3.63-29.54
DRB1*04 4.38 1.72-11.13
Enthesitis at 6 months* 42.5 6.3-1766.6
Enthesitis at 6 months 8.06 1.31-46.96
Enthesitis at 12 months* 22.1 6.1-118.1
Tarsitis at 6 months* 39.2 5.7-1641.1
Tarsitis at 12 months* 8.0 3.1-22.1
Hip arthritis at 6 months 6.34 2.30-17.46
IBP/SIJ* pain at 6 months 10.5 1.1-505.5
IBP at 6 months 16.22 2.16-121.9
Psoriasis 7.23 1.72-30.49
*35 patients with juvenile-onset ankylosing spondylitis compared with 75 patients w
arthritis. OR and 95%CI were recalculated and differ from those reported in the orig
performed.
314 patients with juvenile idiopathic arthritis ref. [61].
In a 15-year extended follow-up of 55 patients with enthesitis related arthritis years
at 6 months (OR 46.73, 95%CI 1.16-39.34; multivariate analysis), and high sedimenta
were associated with radiographic sacroiliitis ref. [63].
OR = odds ratio. 95%CI = 95% confidence intervals. AS = ankylosing spondylitis. ND =and the others had PsA SpA (n = 3), ReA SpA (n = 6), IBD
SpA (n = 1), and u-SpA (n = 17).
The combination of severe sacroiliitis on MRI and
HLA-B27 was highly predictive for AS. The DESIR [68]
study included 708 adults with IBP of <3 years disease
duration. Of this group, 184 (26%) had AS, 77% SpA,
and 67% axial SpA. HLA-B27 positivity was associated
with a younger age at the onset of IBP, less delay in diag-
nosis, lower frequency of psoriasis, and higher frequen-
cies of sacroiliitis and spondylitis on imaging.
The importance of such prospective studies is that up
to one-third of patients with AS fulfill the modified New
York criteria for AS within two years of symptoms and
50% by five years. While cohort studies include patients
with IBP, those studies in retrospect include a significant
number of patients with peripheral symptoms. Despite a
trend for male sex, HLA-B27, and uveitis in patients
with AS, most features of this peripheral AS disease do
not differ from those of patients with axial SpA. Ultim-
ately, these prospective risk factors include some factors
already identified in retrospective studies and help define
and illustrate the relationships between u-SpA, pre-
radiographic AS, and axial and peripheral SpA.
Although Zeidler, et al. [49] proposed four possible out-
comes for u-SpA, only two of them are clearly found in the
rheumatology clinic: 1) a subgroup of patients representingg ankylosing spondylitis after a mean of 12.2 years
of 14.9 years (11.7 to 25.1) ref. [61]
Multlivariate analysis
p OR 95%CI p
0.001 2.92 0.93-9.12 0.066
0.003 9.21 1.11-76.40 0.039
0.000 ND
0.000 5.29 1.63-17.17 0.005










ith systemic, polyarticular, and pauciarthritis type 1 juvenile rheumatoid
inal publication ref. [60]. In this sample, no multivariate analysis was
, DRB1*04 (OR 4.13, 95%CI 1.26-13.46, p = 0.19; univariate analysis), hip arthritis
tion rate for at least 6 month (OR 4.09, 95%CI 1.05-15.91; multivariate analysis)
not determined. IBP = inflammatory back pain. SIJ = sacroiliac joint pain.
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example, AS) and 2) a subgroup consisted of patients with
“definite” u-SpA. The stage between the onset of symptoms
and the demonstration of radiographic sacroiliitis in
patients with u-SpA is the pre-radiographic stage of AS.
This recent ability to recognize u-SpA patients in this
stage, thereby allowing the earlier use of TNF blockers
such as etanercept or infliximab, has appeared to result in
better clinical responses [69]; this improvement has had a
major influence in the development of the concept of axial
SpA [9]. The initial strategy was the identification of
patients with axial symptoms at risk of AS [9-11]; lately,
the a new strategy has evolved in focusing on identification
of those with peripheral disease at risk of axial SpA [12].
Rudwaleit, et al. [9] first calculated the pre-test probabil-
ity of axial SpA and AS among mostly adult patients with
any kind of back pain according to the sensitivity, specifi-
city, and positive likelihood ratio (LR) of SpA features as
appeared in different publications. He built two algorithms
to be used in clinical practice, one starting with the identi-
fication of IBP in patients with back pain and the other
with by HLA-B27 testing alone. The former algorithm
increases the probability of having axial SpA (including
AS) up to around 90% and the latter up to 59%.
Based on real-world clinical findings, Heuft-Doren-
bosch, et al. [66] proposed changes on the level forTable 3 Axial and peripheral spondyloarthritis Assessment of
criteria
Axial spondyloarthritis ref. [11]
Individuals <45 years with back pain >3 months*
Imaging HLA-B27
Sacroiliitis on MR or X-rays Positive test
Additional features need








Good response to non-steroidal antinflammatory drugs
Family history for spondyloarthritis
HLA-B27
Elevated C reactive protein
Classification of individuals as Axial SpA: *Requires two eligibility criteria (age at ons
through MR and another through HLA-B27 testing. The former requires at least one
Classification of individuals as peripheral SpA: Requires at least of three eligibility cr
their diagnostic value.
§Despite axial and peripheral SpA share most additional criteria for classification, th
definitions in tables.
MR =Magnetic Resonance.placing MRI and HLA-B27 in the algorithm. In an-
other study, IBP, HLA-B27, and sacroiliitis by MRI per-
formed well in detecting axial SpA in patients referred
by orthopedists and primary care physicians who had
back pain >3 months, and age at onset of <45 years
[70]. Ultimately, such criteria and algorithms provide
the clinician, particularly the general practitioner and
the orthopedic surgeon, with diagnostic strategies to
differentiate IBP from mechanical back pain.
There is no such analyses yet in juvenile-onset SpA,
but the association of some variables with the develop-
ment of AS and radiographic sacroiliitis suggest a role
for genetic, demographic, and clinical features for the
progression of u-SpA to AS (Table 2). Essential in inter-
preting such information is the recognition that while
the development of axial SpA starts with back pain, data
on juvenile-onset SpA is derived from JIA and JRA data,
conditions whose principal characteristic is not axial
disease, but peripheral arthritis.
Axial and peripheral ASAS SpA criteria
Today, the concept of axial SpA has moved from the non-
radiographic sacroiliitis stage of AS to the wider spectrum
of SpA, including the axial and peripheral categories
[11,12] (Table 3). The ASAS criteria for SpA scope focus
on the two most frequent groups of clinical features: theSpondyloarthritis International Society classification
Peripheral spondyloarthritis ref. [12]
Individuals with arthritis or enthesitis or dactylitis
ed for classification§
At least one At least two
Uveitis Arthritis
Psoriasis Enthesitis (heel pain)
Crohn’s/colitis Dactylitis
Previous infection Inflammatory back pain (ever)
HLA-B27 Family history for SpA
Sacroiliitis on imaging
et and duration of back pain) followed by two different approaches, one
and the latter at least two additional criteria.
iteria (arthritis or enthesitis or dactylitis) plus one or two items depending on
e definition of some individual criteria might be different. Please check such
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tylitis group. In the initial studies of adult patients with IBP
of less than 2 years, these diagnostic and classificatory
properties of both the ASAS axial and peripheral SpA cri-
teria appear to be better than those of reported by Amor,
et al. [37] and ESSG [38] groups and implementation is
under way. Drug efficacy studies are being carried out in
patients with axial SpA to determine the role of TNF
blockers in remission and prevention of structural damage
[71-73].
Nevertheless, there are more issues in axial [11] and
peripheral [12] SpA criteria that need to be considered:
1) The existence of two sets of criteria has academic and
research implications, yet their validation in various
populations and clinical scenarios are needed before
they would be widely used in clinical practice;
2) The cost of MRI and HLA-B27 testing may limit the
applicability of ASAS criteria in countries withTable 4 Definitions of parameters applied in the Assessment of
criteria for axial and peripheral spondyloarthritis
Axial SpA ref. [11]
IBP According to experts (14): ≥4 out of 5 parameters p
(1) age at onset 40 years; (2) insidious onset; (3) imp
with exercise; (4) no improvement with rest; (5) pain
(with improvement upon getting up)
Arthritis Past or present active synovitis diagnosed by a phys
Enthesitis Heel enthesitis: past or present spontaneous pain or
tenderness at examination of the site of the insertio
of the Achilles tendon or plantar fascia at the calcan
Uveitis Past or present uveitis anterior, confirmed by an oph
Dactylitis Past or present dactylitis, diagnosed by a physician
Psoriasis Past or present psoriasis, diagnosed by a physician
IBD Past or present Crohn’s disease or ulcerative colitis d
Good response to NSAIDs 24–48 h after a full dose of a NSAID the back pain is
not present any more or is much better
Family history of SpA Presence in first-degree (mother, father, sisters, broth
aunts, uncles, nieces and nephews) relatives of any o
arthritis; (5) IBD
Elevated CRP CRP concentration above upper normal limit in the
presence of back pain, after exclusion of other
causes for elevated CRP concentration.
HLA-B27 Positive testing according to standard laboratory tec
Radiographic SI Bilateral grade 2–4 or unilateral grade 3–4 sacroiliitis o
SI by MRI Active inflammatory lesions of sacroiliac joints with d
associated with SpA
Preceding infection NA
SpA = spondyloarthritis. IBP = inflammatory back pain. ASAS = Assessment of Spondylo
non-steroidal anti-inflammatory drug. AS = ankylosing spondylitis. IBD = inflammatorybudget restrictions or in segments of the population
not covered by any health security system;
3) Despite the fact that the definition of some variables
listed in both axial and peripheral SpA criteria differ
from each other to avoid classification overlaps, the
existence of different definitions may be confusing
(Table 4);
4) Except for radiographic sacroiliitis, signs and
symptoms in the ASAS criteria for SpA refer to
active inflammatory and not structural damage; and
5) Regarding nomenclature, the term “peripheral SpA”
may appear to be contradictory in itself and confusingThe role of axial and peripheral SpA criteria in children
and adolescents
ASAS criteria for axial and particularly peripheral SpA
may have important implications for the recognition of
children and adolescents with SpA and the understandingSpondyloarthritis International Society classification




IBP in the past according to the rheumatologist’s judgment.
In patients with current IBP (and concomitant peripheral
manifestations), the ASAS classification criteria for axial
SpA should be applied
ician Current peripheral arthritis compatible with SpA
(usually asymmetric and/or predominant involvement of
the lower limbs), diagnosed clinically by a doctor
n
eus.
Enthesitis: past or present spontaneous pain or tenderness
at examination of an entheses.
Any site of enthesitis can be affected whereas in the
ASAS classification criteria for axial SpA only enthesitis of
the heel is considered.
thalmologist
iagnosed by a physician
Not mentioned
ers, children) or second-degree (maternal and paternal grandparents,
f the following: (1) AS; (2) psoriasis; (3) acute uveitis; (4) reactive
Not mentioned
hniques
n plain radiographs, according to the modified New York criteria ref. [3]
efinite bone marrow edema/osteitis, suggestive of sacroiliitis
Urethritis/cervicitis or diarrhoea within 1 month before
the onset of arthritis/enthesitis/dactylitis
Arthritis international Society. IBD = Inflammatory bowel disease. NSAIDs =
bowel disease. CRP = C-reactive protein. MRI = magnetic resonance imaging.
Table 5 European Spondylarthropathy Study Group
classification criteria and results of their validation in
children
Inflammatory back pain or synovitis –symmetric or predominantly
in the lower limbs plus
one of the following
• Positive family history
• Psoriasis
• Inflammatory bowel disease
• Urethritis, cervicitis, or acute diarrhea within one month before arthritis
• Buttock pain alternating between right and left gluteal areas
• Enthesopathy
• Sacroiliitis
Validated in 361 adults with SpA and 455 controls, such criteria showed a
sensitivity of 86.7% and specificity of 87.0% ref. [38].
Validated in 2,982 rheumatic children ref. [74], the diagnostic properties of
those criteria were 78.7% for sensitivity, 92.2% for specificity, 58.8% and 96.8%
for positive and negative predictive values, respectively, 85.3% for positive
likelihood ratio, and 90.3 for diagnostic accuracy. Sensitivity of the criterion
“inflammatory back pain” was only 9.1% in children.
Figure 4 Grade 3 bilateral sacroiliitis in a 14-year-old boy with
6 years disease duration. There is subchondral sclerosis of the iliac
bone, joint surface irregularities, which include some erosions on both
sides, and joint space narrowing of the hips (From Burgos-Vargas, R.
2006, The juvenile-onset spondyloarthritides. In: Weisman MH, van der
Heijde D, Reveille JD. Ankylosing spondylitis and the
Spondyloarthropathies. Mosby. Philadelphia. pp 94–106).
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http://www.ped-rheum.com/content/10/1/14of the relationship between juvenile and adult SpA. Chil-
dren and adults would be classified under the same criteria,
the long-term follow-ups of children with SpA would be
more easily carried out, and the results of clinical trials and
management would be interchangeable to some extent.
Where do this leave us?
Before quickly accepting these ASAS criteria for children
and adolescents, however, it is important to answer two
specific questions:
1) Is there a rationale for alternative criteria for children
with ERA, PsA, and undifferentiated arthritis
according to ILAR criteria? ERA and PsA (andA B
Figure 3 TNF blocker effect on sacrolliitis. Short Tau (t) (inversion time) Inv
sacroiliac joints of a 16-year-old boy a 3-month history of gluteal pain and a 3
14 weeks after 5 mg/kg infliximab treatment at baseline and weeks 2 and 6. I
part of the sacrum inferior quadrant on the opposite side (arrow) that clearedperhaps some cases of undifferentiated arthritis) are
the subgroups representing juvenile-onset SpA in the
ILAR JIA classification criteria for JIA [29]. The
concept of ERA and PsA in ILAR JIA classification
does not correspond to the traditional concept of SpA
because such ILAR criteria precludes the overlapping
of inclusion criteria among different subgroups. Thus,
the features that link ERA and PsA as SpA are the
ones that may be thought to make them incompatible
with each other.ersion Recovery (STIR) magnetic resonance (MR) imaging of the
-year history of peripheral arthritis and enthesitis before (A) and
n (A), there is ample edema of the iliac bone and sacrum (line) and
-up after treatment (B).
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http://www.ped-rheum.com/content/10/1/14In contrast, the concept of SpA behind the ASAS
axial and peripheral SpA criteria [11,12] reflects the Moll
and Wright’s [27] original idea of clinical overlaps
between the different diseases.
This author’s opinion is that we need common con-
cepts and criteria if we want to keep juvenile and adult
onset types of SpA as a disease continuum. Amor,
et al. [37] and ESSG [38] criteria have been validated
in children and at least the latter has been used to
some extent (Table 5). Today, ASAS axial and periph-
eral SpA criteria might be a good substitute for Amor,
et al. [37] and ESSG [38]criteria and perhaps a good al-
ternative to ILAR criteria [29]. Regarding nomencla-
ture, it seems more appropriate for pediatric
rheumatologists to use of the ILAR terms ERA and
PsA than the contradictory term “peripheral SpA” since
most children and adolescents have peripheral disease
and rarely axial symptoms.
2) If needed, which set of ASAS criteria is more
appropriate for children, axial or peripheral? It seems
clear that axial and peripheral SpA classifications have
different purposes. While the former [11] is intended
to identify the spinal and sacroiliac involvement in theFigure 5 Involvement of the feet in patients with SpA. A. Dactylitis of
Diffuse swelling of the tarsal region of a 11- year-old boy with juvenile-ons
blenorrhagica spots in a 16-year-old boy with chronic reactive arthritis. D. D
Achilles, peroneal and tibial posterior tendons in a 12 year-old-boy with un
Reactive arthritides. In: Cassidy JT, Petty RE (eds): Textbook of Pediatric Rhe
and Burgos-Vargas, R. 2006, The juvenile-onset spondyloarthritides. In: Weis
Spondyloarthropathies. Mosby. Philadelphia. pp 94–106).early inflammatory stage of AS, the latter [12] relies
on peripheral arthritis, enthesitis, and dactylitis as
entry criteria (Table 3).
Regarding axial involvement, children and adoles-
cents may have both active sacroiliitis on MRI (Figure 3)
and radiographic sacroiliitis grade 2 bilateral or grades 2
or 4 unilateral (Figure 4), but in most cases these events
occur in association with peripheral arthritis and enthe-
sitis (Figure 5).
Axial symptoms, as isolated features, are unusual in
youngsters. The ASAS axial SpA criteria suggest the
need for a history of back pain for at least three months
as entry criteria before performing MRI and/or radio-
graphic studies of the sacroiliac joints. There seems to
be no clear clinical rationale to perform MRI studies of
the sacroiliac joints and the spine in children in the ab-
sence of back pain. Certainly, the logical criteria for chil-
dren and adolescents is the ASAS peripheral SpA
criteria since they include the most important signs and
symptoms in patients with juvenile-onset SpA.
Except for “good response to NSAIDs”, on that no
specific reports in children exist, children and adoles-
cents with juvenile-onset SpA could well fulfill allthe third digit in a 12-year-old boy with undifferentiated SpA. B.
et AS. C. Tarsal swelling, hyperextension of the digits, and keratoderma
iffuse swelling of the posterior aspect of feet including the ankles,
differentiated SpA (Modified from Burgos-Vargas R, Vázquez-Mellado J.
umatology. 5th Edition. Philadelphia. Elsevier Saunders. 2005:604–612
man MH, van der Heijde D, Reveille JD. Ankylosing spondylitis and the
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http://www.ped-rheum.com/content/10/1/14axial and peripheral ASAS SpA criteria (Table 6). The
diagnostic properties of some of these criteria were
determined during the validation of the Amor et al.
[37] and ESSG [38] classification criteria of SpA [74]
and in a comparative study of juvenile-onset AS and
u-SpA with JRA [60]. As expected, the sensitivity of
back pain in the validation study of SpA according
ESSG [38] was very low, but its specificity very high
(Table 5). In the latter study, sensitivity, specificity,
and + LR of tarsitis and enthesopathy were very high
suggesting that tarsitis should be considered an add-
itional criterion in any classification criteria (Figure 6).
The frequency of each criterion depends on the classi-
fication category. By definition, for example, IBP and
radiographic sacroiliitis should be found in all patients
with AS, whereas arthritis or enthesitis should be
found in all patients with ERA. On the other hand,
the definition of each criterion and its diagnostic value
should be assessed in children.
The question of whether ASAS criteria for axial
and peripheral SpA [11,12] have any role in the classi-
fication of children with SpA, ERA, PsA, and evenTable 6 Estimated prevalence of each of the items listed in th
































Previous infection + -
*Based on the literature and on the opinion of local experts in the care of these ch
The presence of such items excludes the undifferentiated spondyloarthritis and ent
MRI = magnetic resonance imaging. NSAIDs = Non-Steroidal Antinflammatory Drugsundifferentiated arthritis remains to be determined.
Ideally, all related clinical conditions in children and
adults should be encompassed under the same criteria
in order to facilitate scientific communication and
patients transition from childhood to adulthood med-
ical care. From the therapeutic point of view, there
should be some advantages if the management of ju-
venile and adult onset forms could have the same op-
portunity to be treated in the early inflammatory stage
of the disease.
Conclusions
The dilemma of how to apply adult AS and related
SpA criteria to children has challenged pediatric rheu-
matologists for decades. The ILAR JIA criteria for PsA
and ERA do not corresponds well with adult AS cri-
teria. The new ASAS criteria offer rheumatologists a
chance to reexamine how children with SpA, ERA,
PsA, and undifferentiated arthritis can fit and not fit
into these new criteria. Adult and pediatric rheumatol-
ogists want to diagnose these patients described by
the ASAS criteria early and be able to offer thesee Assessment of Spondyloarthritis International Society
























hesitis related arthritis as diagnosis.
. NA = data not available. SpA = Spondyloarthritis.
Figure 6 Composite images of ankylosing tarsitis in a 16-year-old boy with AS of 9 year’s disease duration and complete ankylosis of
the tarsal bones and grade 2 bilateral sacroiliitis. A and B. Flat foot and swelling around the ankle. C, D, E, and F. T2-weighted-fat suppressed
MR imaging showing edema in various tarsal bones, joint spaces (C and D), and soft tissues (E and F) surrounding the tendons of the posterior aspect
of the foot on the coronal view (arrows) fat. G. Complete ankylosis of the tarsal bones and an enthesophyte at the plantar fascia attachment (modified
from: Burgos-Vargas R. A case of childhood-onset ankylosing spondylitis: diagnosis and treatment. Nat Clin Pract Rheumatol 2009;5:52–7).
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http://www.ped-rheum.com/content/10/1/14patients aggressive TNF inhibitor therapy, when pos-
sible and affordable, to possibly prevent joint and
bone damage.
The application of those specific strategies in children
and adolescents with SpA is challenging as the most im-
portant manifestation in the early stage of disease is not
inflammatory back pain as it is in adults, but peripheral
arthritis and enthesitis. In this instance, the best ap-
proach to juvenile onset SpA according to ASAS criteria
may be not to use the axial criteria but rather to use the
peripheral set of criteria. The question of whether
pediatric rheumatology needs new separate criteria for
SpA, ERA, PsA, and undifferentiated arthritis remains
controversial and goes against our need to encompass
such similar adult and pediatric diseases under the um-
brella of one set of criteria.Competing interests
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